Europe — EMA
Carduran Cr (Doxazosin Mesilate)
Carduran Cr is a medication containing doxazosin mesilate, used primarily for managing high blood pressure and benign prostatic hyperplasia (BPH). This extended
Request sourcing
What is Doxazosin Mesilate?
Carduran Cr is a medication containing doxazosin mesilate, used primarily for managing high blood pressure and benign prostatic hyperplasia (BPH). This extended-release formulation is designed for oral use and is manufactured by Upjohn Eesv in the EU.
What is Doxazosin Mesilate used for?
Carduran Cr is commonly used to treat high blood pressure, helping to lower blood pressure levels and reduce the risk of associated complications. Additionally, it is used for managing symptoms of benign prostatic hyperplasia (BPH), such as difficulty urinating. The medication works by relaxing certain muscles in the body, including those in the prostate and bladder neck, which can improve urine flow and reduce symptoms.
What are the side effects of Doxazosin Mesilate?
Common effects of Carduran Cr may include dizziness, fatigue, and headache. Some users may also experience swelling in the hands or feet, nausea, or a dry mouth. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare professional.
What precautions apply to Doxazosin Mesilate?
Carduran Cr should be handled with care, especially for individuals with a history of low blood pressure or liver disease. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Avoid sudden changes in posture to prevent dizziness or fainting.
What does Doxazosin Mesilate interact with?
Carduran Cr may interact with other medications, including those used to treat high blood pressure, depression, or certain antibiotics. Alcohol consumption should be avoided as it can enhance the dizziness effects of the medication. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.



